Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — H1 2025 Earnings Presentation
19 slides from Wuxi Apptec Co., Ltd. Class A's earnings presentation, Jul 29, 2025
Slide 1: WuXi AppTec First Half 2025 Results
WuXi AppTec First Half 2025 Results July 29, 2025 1 603259.SH / 2359.HK
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: Agenda
01 Results Overview 02 Segment Performance 03 Financial Performance 04 Company Outlook 3 Note: Unless otherwise stated, all financials disclosed in this presentation are prepared based on IFRSs. The currency is RMB. All net profit disclosed in this presentation represents net profit attributable to
Slide 4: 1. Results Overview
1. Results Overview 4
Slide 5: Q2 and H1 2025 Revenue & Profit Achieved Strong Growth
Q2 and H1 2025 Revenue & Profit Achieved Strong Growth; H1 Revenue from Continuing Operations Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY Revenue Adjusted Non-IFRS Net Profit RMB billion RMB billion Adjusted Non-IFRS NPM +20.6% +24.2%1 +44.4% Revenue from Continuing Operations 25.4%
Slide 6: Continuous Capacity Expansion; Backlog for Continuing Operations Up 37.2% YoY
With Continuous Capacity Expansion to Better Meet Customer Demand, Backlog for Continuing Operations1 Up 37.2% YoY as of June 30, 2025 Backlog for Continuing Operations1 RMB billion +37.2% 56.69 52.16 49.06 41.32 42.40 35.28 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 6 Note: 1. As disclosed in
Slide 7: Diversified Revenue Streams of Continuing Operations Across Regions
Diversified Revenue Streams of Continuing Operations from Customers Across Regions Ensure the Stability and Resilience of the Company’s Financial Performance RMB billion China Europe 3.15Bn，-5.2% 2.33Bn，+9.2% Revenue contribution: 15% Revenue contribution: 11% US 14.03Bn，+38.4% Revenue contribution:
Slide 8: Advancing Sustainability, Extensively Recognized by Global Rating Agencies
Advancing Sustainability, Extensively Recognized by Global Rating Agencies Achieved the Highest “AAA” Rating from MSCI for the First Time, Becoming the First A-share Listed Company in Life Sciences Industry to Reach This Milestone; Near-term Emissions Reduction Targets Validated by SBTi Achieved MSC
Slide 9: 2. Segment Performance
2. Segment Performance ze S| od
Slide 10: WuXi Chemistry: CRDMO Business Model Drives Continuous Growth
WuXi Chemistry: CRDMO Business Model Drives Continuous Growth, H1 2025 Revenue Up 33.5% YoY, with TIDES Revenue Up 141.6% YoY Revenue & Gross Profit Margin CRDMO Business Model Drives Continuous Growth ⚫ WuXi Chemistry H1 revenue up 33.5% YoY to 16.30bn ⚫ With continued optimization of production pr
Slide 11: WuXi Chemistry: Small Molecule CRDMO Pipeline Converts and Captures Molecules
WuXi Chemistry: Driven by “Follow the Molecule + Win the Molecule”, Small Molecule CRDMO Pipeline Efficiently Converts and Captures High-Quality Molecules, Delivering Sustained Growth “R” 2%↓ 440,000+ 14,751 compounds Compounds H1 2025 Newly Added Molecules to D&M Pipeline 2,881 Preclinical & Phase
Slide 12: WuXi Testing: Drug Safety Evaluation Service & SMO Maintain Leading Positions
WuXi Testing1: Drug Safety Evaluation Service & SMO Maintain Leading Positions Revenue & Gross Profit Margin1 Lab Testing Services1 ⚫ Q2 revenue of lab testing services reached 1.00bn, up 5.5% YoY and 13.2% QoQ. RMB billion Of which, drug safety evaluation services revenue up 3.4% YoY and 10.2% QoQ
Slide 13: WuXi Biology: Continues to Generate Downstream Opportunities
WuXi Biology: Continues to Generate Downstream Opportunities; In Vitro & In Vivo Business Synergies and New Modality Business Drive Growth Revenue & Gross Profit Margin RMB billion ⚫ Follow the science and continuously strengthen drug discovery capabilities in emerging areas. Efficiently generate do
Slide 14: 3. Financial Performance
3. Financial Performance 14
Slide 15: Continuously Improve Operating Efficiency and Leverage Management Resilience
Continuously Improve Operating Efficiency and Leverage Management Resilience, Further Enhancing Profitability Adjusted Non-IFRS Gross Profit Adjusted Non-IFRS GPM* Adjusted Non-IFRS Net Profit Adjusted Non-IFRS NPM RMB billion RMB billion 40.3% 38.0% 38.7% 42.0% 41.6% 39.8% 44.5% 22.0% 22.4% 23.9% 2
Slide 16: H1 2025 Operating Cash Flow Up 49.1% YoY to 7.07 Billion
With Continued Business Growth, Efficient Operations and Constant Improvement of Financial Management Capabilities, H1 2025 Operating Cash Flow Up 49.1% YoY to 7.07 Billion RMB billion Capex1 12.64 Operating Cash Flow 11.99 9.97 10.23 6.94 7.07 5.52 4.38 3.83 4.00 3.03 H1 2024 2.10 4.74 H1 2024 1.51
Slide 17: 4. Company Outlook
4. Company Outlook i ls Be 3)
Slide 18: Company Outlook
Company Outlook Focus on the CRDM"O" business model, striving for highly efficient & exceptional services and lean operations ("O") • Continue to focus on our unique integrated CRDMO core business, and accelerate global expansion and capacity construction • Leveraging customers’ ongoing demand for e
Slide 19: Company Outlook
Company Outlook Remain committed to rewarding shareholders and upholding the Company's value • Distributed a total of RMB3.84 billion in cash dividends in H1, including RMB2.83 billion for 2024 annual cash dividend and RMB1.01 billion for 2025 special cash dividend • Share repurchases and cancellati